Halozyme Therapeutics Inc (HALO)
63.72
-0.76
(-1.18%)
USD |
NASDAQ |
Mar 28, 12:40
Halozyme Therapeutics Shareholders Equity (Quarterly): 363.82M for Dec. 31, 2024
View 4,000+ Financial Data Types:
Add
Browse
Shareholders Equity (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Shareholders' Equity Definition
Shareholder's Equity is a main portion of the balance sheet of a company that measures the net value of a company. The reason for this is because the from an accounting perspective, the balance sheet equation is Shareholder's Equity = Assets - Liabilities. A few examples of shareholder's equity of a company include retained earnings, paid in capital, and preferred stock.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| Biomarin Pharmaceutical Inc | 5.658B |
| Johnson & Johnson | 71.49B |
| Catalyst Pharmaceuticals Inc | 727.63M |
| Merck & Co Inc | 46.31B |
| AIM ImmunoTech Inc | 2.912M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 2.063B |
| Total Liabilities (Quarterly) | 1.700B |
| Debt to Equity Ratio | 4.139 |
| Current Ratio | 7.803 |
| Net Debt Paydown Yield | -0.03% |